2015
DOI: 10.1016/j.otc.2015.06.004
|View full text |Cite
|
Sign up to set email alerts
|

Management of Children with Severe, Severe-profound, and Profound Sensorineural Hearing Loss

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
4
0

Year Published

2016
2016
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(4 citation statements)
references
References 66 publications
0
4
0
Order By: Relevance
“…In patients with severe to profound hearing loss who are unable to benefit from hearing aids, a cochlear implant may provide significant benefit . Cochlear implants are surgically placed devices that directly stimulate auditory neural pathways in the cochlea.…”
Section: Introductionmentioning
confidence: 99%
“…In patients with severe to profound hearing loss who are unable to benefit from hearing aids, a cochlear implant may provide significant benefit . Cochlear implants are surgically placed devices that directly stimulate auditory neural pathways in the cochlea.…”
Section: Introductionmentioning
confidence: 99%
“…Caregivers' commitment to rehabilitation is another important factor to be highlighted in the post-surgical process. Regular visits to the therapist associated with family engagement are essential points for the best possible performance to be achieved (13) . The caregivers of the children presented here have shown an appropriate engagement, with 100% attendance at rehabilitation sessions.…”
Section: Discussionmentioning
confidence: 99%
“…As a result of the UNHS, diagnosis before three months of age and intervention before 6 months can be achieved for pediatric hearing loss (Expert Group on Universal Newborns Hearing Screening of the National et al 2018). To maximize the opportunity for spoken language, cochlear implant (CI) surgery is the most effective method of hearing rehabilitation for children with severe to profound sensorineural hearing loss (SNHL) (Brookhouser et al 1990; Iseli & Buchman 2015). The Food and Drug Administration candidacy criteria have expanded to include profound SNHL in children as young as 9 months old in 2020 (FDA (U.S. Food & Drug Administration) 2020).…”
Section: Introductionmentioning
confidence: 99%